BIT Capital GmbH Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

BIT Capital GmbH acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 53,928 shares of the biopharmaceutical company’s stock, valued at approximately $2,114,000. BIT Capital GmbH owned about 0.07% of Xenon Pharmaceuticals as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of XENE. Vestal Point Capital LP grew its holdings in Xenon Pharmaceuticals by 57.1% during the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock worth $32,480,000 after buying an additional 300,000 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Xenon Pharmaceuticals by 1,263.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock worth $38,456,000 after acquiring an additional 905,129 shares during the last quarter. Barclays PLC grew its stake in shares of Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after acquiring an additional 13,903 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at about $4,132,000. Finally, Assenagon Asset Management S.A. lifted its position in shares of Xenon Pharmaceuticals by 12.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company’s stock valued at $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Down 0.3 %

Shares of XENE stock opened at $34.78 on Thursday. The firm has a market cap of $2.66 billion, a P/E ratio of -12.33 and a beta of 1.26. The company has a 50 day moving average of $37.90 and a 200-day moving average of $39.79. Xenon Pharmaceuticals Inc. has a 12-month low of $33.27 and a 12-month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.52% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.